Latest Organofluorides Stories
A University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) draws a line from mutation of the gene NTRK1, to its role as an oncogene in non-small cell lung cancer, to treatment that targets this mutation.
- Ceritinib achieved overall response rate of 58.5%, with a median progression-free survival of 8.2 months1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today announced data showing
Can-Fite's CF102 has FDA's Orphan Drug Designation for the treatment of advanced hepatocellular carcinoma PETACH TIKVA, Israel, June 2, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd.
Mylan will launch all strengths at earliest market formation PITTSBURGH, June 2, 2014 /PRNewswire/ -- Mylan Inc.
Phase III data for lenvatinib to be presented at ASCO WOODCLIFF LAKE, N.J., May 31, 2014 /PRNewswire/ -- Eisai Inc.
Retrospective Analysis Demonstrates Survival Benefits for Patients with Stable and Progressive Disease after HD IL-2 in the Modern Era Suggesting Appropriate Drug Sequencing May Improve Outcomes
- 7 total abstracts accepted for afatinib and other compounds from the company's oncology research program RIDGEFIELD, Conn., May 30, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced
The Firm has filed a number of Risperdal lawsuits in the Pennsylvania proceeding on behalf of clients who allegedly developed gynecomastia (male breast growth) due to their use of Risperdal.
Indication of Anticancer Agent Halaven for Use in Earlier-Line Treatment of Advanced Breast Cancer Tokyo, May 27, 2014 - (JCN Newswire)
The Firm is currently offering free and confidential Lipitor lawsuit evaluations to individuals who may have developed Type 2 diabetes after taking the cholesterol-lowering statin.